Astrazeneca (AZN) Revenue (2016 - 2026)

Astrazeneca has reported Revenue over the past 16 years, most recently at $15.3 billion for Q1 2026.

For Q1 2026, Revenue rose 12.51% year-over-year to $15.3 billion; the TTM value through Mar 2026 reached $60.4 billion, up 9.93%, while the annual FY2025 figure was $58.7 billion, 6263.92% up from the prior year.
Revenue for Q1 2026 was $15.3 billion at Astrazeneca, down from $15.5 billion in the prior quarter.
Over five years, Revenue peaked at $15.5 billion in Q4 2025 and troughed at $10.6 billion in Q3 2022.
A 5-year average of $12.8 billion and a median of $12.7 billion in 2024 define the central range for Revenue.
On a YoY basis, Revenue climbed as much as 89.85% in 2022 and fell as far as 10.1% in 2022.
Year by year, Revenue stood at $10.8 billion in 2022, then increased by 11.35% to $12.0 billion in 2023, then grew by 23.84% to $14.9 billion in 2024, then increased by 4.11% to $15.5 billion in 2025, then decreased by 1.39% to $15.3 billion in 2026.
Business Quant data shows Revenue for AZN at $15.3 billion in Q1 2026, $15.5 billion in Q4 2025, and $15.2 billion in Q3 2025.

Peer Comparison